No connection

Search Results

BGM vs JNJ

BGM
BGM Group Ltd.
BEARISH
Price
$3.72
Market Cap
$746.3M
Sector
Healthcare
AI Confidence
85%
JNJ
Johnson & Johnson
NEUTRAL
Price
$244.85
Market Cap
$590.06B
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
BGM
--
JNJ
22.22
Forward P/E
BGM
--
JNJ
19.48
P/B Ratio
BGM
2.01
JNJ
7.23
P/S Ratio
BGM
24.99
JNJ
6.26
EV/EBITDA
BGM
-29.15
JNJ
18.27

Profitability

Gross Margin
BGM
2.92%
JNJ
68.08%
Operating Margin
BGM
-5.41%
JNJ
23.97%
Profit Margin
BGM
-26.32%
JNJ
28.46%
ROE
BGM
-16.52%
JNJ
35.03%
ROA
BGM
-3.84%
JNJ
8.68%

Growth

Revenue Growth
BGM
-56.9%
JNJ
9.1%
Earnings Growth
BGM
0.0%
JNJ
48.6%

Financial Health

Debt/Equity
BGM
0.0
JNJ
0.6
Current Ratio
BGM
7.05
JNJ
1.03
Quick Ratio
BGM
5.94
JNJ
0.69

Dividends

Dividend Yield
BGM
--
JNJ
2.13%
Payout Ratio
BGM
0.0%
JNJ
46.6%

AI Verdict

BGM BEARISH

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score and negative profitability metrics raise concerns. The company is unprofitable with a -26.32% profit margin, -5.41% operating margin, and negative ROE and ROA, while revenue has collapsed by 56.90% year-over-year. Valuation multiples are extremely high with a Price/Sales ratio of 24.99 despite deteriorating fundamentals, and the stock has lost 90.8% of its value over five years. Although the balance sheet shows no debt and strong liquidity ratios, the lack of earnings, cash flow data, and analyst coverage suggests high uncertainty and limited investor confidence.

Strengths
Piotroski F-Score of 6/9 indicates stable financial health relative to distressed peers
Exceptionally strong liquidity with a Current Ratio of 7.05 and Quick Ratio of 5.94
Zero debt (Debt/Equity = 0.00), reducing solvency risk
Risks
Severe profitability issues: -26.32% profit margin and -16.52% ROE
Catastrophic revenue decline of -56.90% YoY, far worse than peer average
Price/Sales of 24.99 is extremely high for a shrinking, unprofitable company
JNJ NEUTRAL

JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (28.5% margin)
Strong ROE of 35.0%
Risks
Premium vs Graham Number ($91.63)
Weak financial trend (Piotroski F-Score: 3/9)

Compare Another Pair

BGM vs JNJ: Head-to-Head Comparison

This page compares BGM Group Ltd. (BGM) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile